Document is current
Any future updates will be listed below
-
Authors
Hou, Yu
Sun, Linyu
LaFleur, Martin W. https://orcid.org/0000-0002-5017-774X
Huang, Linglin
Lambden, Conner
Thakore, Pratiksha I.
Geiger-Schuller, Kathryn
Kimura, Kimitoshi
Yan, Longjun
Zang, Yue
Tang, Ruihan
Shi, Jingwen
Barilla, Rocky https://orcid.org/0000-0002-8062-7246
Deng, Liwen
Subramanian, Ayshwarya https://orcid.org/0000-0002-4134-7612
Wallrapp, Antonia
Choi, Hee Sun
Kye, Yoon-Chul https://orcid.org/0000-0003-0261-5247
Ashenberg, Orr
Schiebinger, Geoffrey
Doench, John G. https://orcid.org/0000-0002-3707-9889
Chiu, Isaac M. https://orcid.org/0000-0002-0723-4841
Regev, Aviv https://orcid.org/0000-0003-3293-3158
Sharpe, Arlene H. https://orcid.org/0000-0002-9736-2109
Kuchroo, Vijay K. https://orcid.org/0000-0001-7177-2110
- License Information
-
More Information
Article History
Received: 11 August 2022
Accepted: 13 September 2024
First Online: 16 October 2024
Competing interests
: V.K.K. has an ownership interest in Tizona Therapeutics, Bicara Therapeutics, Larkspur Biosciences and Werewolf Therapeutics; financial interests in Biocon Biologics, Perkin Elmer, Elpiscience Biopharmaceutical, Equilium and Syngene. A.H.S. has patents/pending royalties on the PD-1 pathway from Roche and Novartis; is on advisory boards for Surface Oncology, SQZ Biotechnologies, Elpiscience, Selecta, Bicara Therapeutics, Monopteros, Fibrogen, Alixis, GlaxoSmithKline and Janssen; and has received research funding from Merck, Vertex, Moderna, Quark/Iome and AbbVie (unrelated to this project). A.R. is listed as a co-inventor on patent applications filed by the Broad Institute for inventions related to single-cell genomics; is an equity holder in Immunitas; and was a scientific advisory board member of Thermo Fisher Scientific, Syros Pharmaceuticals, Neogene Therapeutics and Asimov until 31 July 2020. From 1 August 2020, A.R. is an employee of Genentech and has equity in Roche. The other authors declare no competing interests.
